|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
WLY018679064 |
| 003 |
DE-627 |
| 005 |
20240530092353.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240530s2024 xx |||||o 00| ||und c |
| 024 |
7 |
|
|a 10.1111/pim.13037
|2 doi
|
| 028 |
5 |
2 |
|a 2024-05-30_PIM_2024_46_5.zip.xml
|
| 035 |
|
|
|a (DE-627)WLY018679064
|
| 035 |
|
|
|a (WILEY)PIM13037
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 100 |
1 |
|
|a Soyer, Tauane Gonçalves
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis
|
| 264 |
|
1 |
|c 2024
|
| 300 |
|
|
|a 14
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a © 2024 John Wiley & Sons Ltd.
|
| 520 |
|
|
|a ABSTRACT The treatment for visceral leishmaniasis (VL) causes toxicity in patients, entails high cost and/or leads to the emergence of resistant strains. No human vaccine exists, and diagnosis presents problems related to the sensitivity or specificity of the tests. Here, we tested two phage clones, B1 and D11, which were shown to be protective against Leishmania infantum infection in a murine model as immunotherapeutics to treat mice infected with this parasite species. The phages were used alone or with amphotericin B (AmpB), while other mice received saline, AmpB, a wild‐type phage (WTP) or WTP/AmpB. Results showed that the B1/AmpB and D11/AmpB combinations induced polarised Th1‐type cellular and humoral responses, which were primed by high levels of parasite‐specific IFN‐γ, IL‐12, TNF‐α, nitrite and IgG2a antibodies, which reflected in significant reductions in the parasite load in distinct organs of the animals when analyses were performed 1 and 30 days after the treatments. Reduced organic toxicity was also found in these animals, as compared with the controls. In conclusion, preliminary data suggest the potential of the B1/AmpB and D11/AmpB combinations as immunotherapeutics against L. infantum infection.
|
| 700 |
1 |
|
|a Bandeira Câmara, Raquel Soares
|4 aut
|
| 700 |
1 |
|
|a Pereira, Isabela Amorim Gonçalves
|4 aut
|
| 700 |
1 |
|
|a Ramos, Fernanda Fonseca
|4 aut
|
| 700 |
1 |
|
|a Jesus, Marcelo Moreira
|4 aut
|
| 700 |
1 |
|
|a Ludolf, Fernanda
|4 aut
|
| 700 |
1 |
|
|a Paula Costa, Guilherme
|4 aut
|
| 700 |
1 |
|
|a Lage, Daniela Pagliara
|4 aut
|
| 700 |
1 |
|
|a Freitas, Camila Simões
|4 aut
|
| 700 |
1 |
|
|a Vale, Danniele Luciana
|4 aut
|
| 700 |
1 |
|
|a Pimenta, Breno Luiz
|4 aut
|
| 700 |
1 |
|
|a Martins, Vívian Tamietti
|4 aut
|
| 700 |
1 |
|
|a Galdino, Alexsandro Sobreira
|4 aut
|
| 700 |
1 |
|
|a Chávez‐Fumagalli, Miguel Angel
|4 aut
|
| 700 |
1 |
|
|a Roatt, Bruno Mendes
|4 aut
|
| 700 |
1 |
|
|a Sousa Vieira Tavares, Grasiele
|4 aut
|
| 700 |
1 |
|
|a Coelho, Eduardo Antonio Ferraz
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Parasite Immunology
|g 46(2024), 5
|w (DE-627)WLY012322709
|x 13653024
|7 nnns
|
| 773 |
1 |
8 |
|g volume:46
|g year:2024
|g number:5
|g extent:14
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_WLY
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_110
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_206
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_618
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2035
|
| 912 |
|
|
|a GBV_ILN_2105
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 46
|j 2024
|e 5
|g 14
|